The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Abstract
Varenicline, a new nicotinic ligand based on the structure of cytisine, has recently been approved by the U.S. Food and Drug Administration for use as a smoking cessation aid. Varenicline has been shown to be a partial agonist of alpha4beta2 receptors, and in equilibrium binding assays, it is highly selective for the alpha4beta2 receptor. In this study, we have examined the functional activity of varenicline at a variety of rat neuronal nicotinic receptors expressed in Xenopus laevis oocytes and assayed under two-electrode voltage clamp. We also find that varenicline is a potent, partial agonist at alpha4beta2 receptors, with an EC50 of 2.3 +/- 0.3 microM and an efficacy (relative to acetylcholine) of 13.4 +/- 0.4%. Varenicline has lower potency and higher efficacy at alpha3beta4 receptors, with an EC50 of 55 +/- 8 microM and an efficacy of 75 +/- 6%. Varenicline also seems to be a weak partial agonist at alpha3beta2 and alpha6-containing receptors, with an efficacy <10%. It is remarkable that varenicline is a potent, full agonist at alpha7 receptors with an EC50 of 18 +/- 6 microM and an efficacy of 93 +/- 7% (relative to acetylcholine). Thus, whereas varenicline is a partial agonist at some heteromeric neuronal nicotinic receptors, it is a full agonist at the homomeric alpha7 receptor. Some combination of these actions may be involved in the mechanism of varenicline as a smoking cessation aid.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varenicline is a partial agonist of α4/β2* nAChRs (Coe et al., 2005), but also activates α7-type nAChRs (Mihalak et al., 2006).”
From It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood (2008) · cites this paper as Mihalak et al., 2006
In the citing paper
“Varenicline (Chantix; Pfizer, Groton, CT) is a potent partial agonist at ␣42 nAChRs, with 40 to 60% of the agonist efficacy of nicotine (Rollema et al., 2007), and it is a less potent partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007Rollema et al., , 2009b)).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Mihalak et al., 2006
In the citing paper
“the high-affinity ␣42 partial agonist varenicline also has moderate affinity for other nAChRs and acts as a partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Mihalak et al., 2006
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [6]
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [6]
In the citing paper
“It acts as a partial agonist at α3β4-, α2-, and α6-containing nAChRs, and a full agonist at α7 nAChRs [238].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [238]
In the citing paper
“It is a derivative of cytisine, a plant alkaloid with selective affinity and partial agonism for α4β2 nAChRs [236–238].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [238]
In the citing paper
“It is a derivative of cytisine, a plant alkaloid with selective affinity and partial agonism for α4β2 nAChRs [236–238].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [237]
In the citing paper
“subsequent work showed that varenicline had a significant effect at ␣7 nAChRs, ␣34* nAChRs, and 5-hydroxytryptamine type 3 receptors”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Mihalak et al., 2006
In the citing paper
“varenicline, a partial agonist of the α4β2 nAChRs and a full α7 agonist developed to aid smoking cessation in humans (Mihalak, Carroll, & Luetje, 2006), has also been found to have antidepressant effects in the FST (Rollema et al., 2009).”
From Nicotine addiction and psychiatric disorders (2015) · cites this paper as Mihalak et al., 2006
Citations
Cites
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Nicotinic Receptors at the Amino Acid Level
Corringer, P., Novère, N. G. L., & Changeux, J. (2000) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.431 · Cited by 832
Luetje, C., & Patrick, J. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-03-00837.1991 · Cited by 558
Jensen, A. A., Frølund, B., Liljefors, T., & Krogsgaard‐Larsen, P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040219e · Cited by 549
Chavez-Noriega, L. E., Crona, J. H., Washburn, M. S., Urrutia, A., Elliott, K. J., & Johnson, E. C. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36376-1 · Cited by 405
Salminen, O., Murphy, K. L., McIntosh, J. M., Drago, J., Marks, M. J., Collins, A. C., & Grady, S. R. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1526 · Cited by 401
Chavez-Noriega, L. E., Crona, J. H., Washburn, M. S., Urrutia, A., Elliott, K. J., & Johnson, E. C. (1997) · PubMed · Cited by 392
Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit
Papke, R. L., & Heinemann, S. F. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09896-7 · Cited by 259
Comparative pharmacology of rat and human α7 nAChR conducted with net charge analysis
Papke, R. L., & Porter Papke, J. K. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704833 · Cited by 249
Human α6 AChR subtypes: subunit composition, assembly, and pharmacological responses
Kuryatov, A., Olale, F., Cooper, J., Choi, C. H., & Lindstrom, J. M. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00144-1 · Cited by 224
Flagged first, then by citations
1 of the 26 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 583
Guy, E. G., Fisher, D. C., Higgins, G. A., & Fletcher, P. J. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000092 · Cited by 17
Bolchi, C., Bavo, F., Gotti, C., Fumagalli, L., Fasoli, F., Binda, M., Mucchietto, V., Sciaccaluga, M., Plutino, S., Fucile, S., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.048 · Cited by 17
Laikowski, M. M., Reisdorfer, F., & Moura, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180410105135 · Cited by 17
Koga, M., Kanaoka, Y., Inada, K., Omine, S., Kataoka, Y., & Yamauchi, A. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.01.012 · Cited by 17
New Findings on Nicotine Addiction and Treatment
Rose, J. E. (2008) · Nebraska Symposium on Motivation/The Nebraska symposium on motivation · doi:10.1007/978-0-387-78748-0_8 · Cited by 17
Design, Synthesis and Discovery of Picomolar Selective α4β2 Nicotinic Acetylcholine Receptor Ligands
Yenugonda, V. M., Xiao, Y., Levin, E. D., Rezvani, A. H., Tran, T. P., Al‐Muhtasib, N., Sahibzada, N., Xie, T., Wells, C., Slade, S. K., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4008455 · Cited by 17
Pittenger, S. T., Barrett, S. T., Chou, S., & Bevins, R. A. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.11.033 · Cited by 16
Patkar, O. L., Belmer, A., Tarren, J. R., Holgate, J. Y., & Bartlett, S. E. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.09.048 · Cited by 17
Simmons, S. J., & Gould, T. J. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12171 · Cited by 18
Hone, A. J., McIntosh, J. M., Rueda‐Ruzafa, L., Passas, J., Guerín, C. D. C., Blázquez, J., Enguita, C. G., & Albillos, A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13883 · Cited by 15
Barrett, S. T., Geary, T. N., Steiner, A. N., & Bevins, R. A. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000404 · Cited by 18
Koga, M., Kanaoka, Y., Ohkido, Y., Kubo, N., Ohishi, K., Sugiyama, K., Yamauchi, A., & Kataoka, Y. (2014) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2014.10.150 · Cited by 17
Integrative Pharmacology in the Treatment of Substance Use Disorders
Donlon, J., Kumari, P., Varghese, S. P., Bai, M. Y., Florentin, O. D., Frost, E. D., Banks, J., Vadlapatla, N., Kam, O., Shad, M. U., et al. (2023) · Journal of Dual Diagnosis · doi:10.1080/15504263.2023.2293854 · Cited by 15
Hoestgaard-Jensen, K., Hoestgaard-Jensen, K., & Jensen, A. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.509356 · Cited by 15
Nicotinic receptor partial agonists modulate alcohol deprivation effect in C57BL/6J mice
Sajja, R. K., & Rahman, S. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.07.009 · Cited by 15
Human nicotinic receptors in chromaffin cells: characterization and pharmacology
Albillos, A., & McIntosh, J. M. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-2073-0 · Cited by 16
Hone, A. J., Rueda‐Ruzafa, L., Gordon, T. J., Gajewiak, J., Christensen, S. B., Dyhring, T., Albillos, A., & McIntosh, J. M. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14966 · Cited by 15
Breining, S. R., Melvin, M. S., Bhatti, B. S., Byrd, G. D., Kiser, M. N., Hepler, C. D., Hooker, D. N., Zhang, J., Reynolds, L. A., Benson, L. R., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3011299 · Cited by 15
Alpha3* and alpha 7 nAChR-mediated Ca2+ transient generation in IMR-32 neuroblastoma cells.
Ween, H., Thorin‐Hagene, K., Andersen, E., Grønlien, J. H., Lee, C.-H., Gopalakrishnan, M., & Malysz, J. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.06.005 · Cited by 16
La importancia de tratar la dependencia tabáquica
McRobbie, H. J., & Thornley, S. (2008) · Revista Española de Cardiología · doi:10.1157/13123068 · Cited by 17
Batsikadze, G., Paulus, W., Hasan, A., Grundey, J., Kuo, M., & Nitsche, M. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-01428-6 · Cited by 16
Rollema, H., Russ, C., Lee, T. C., Hurst, R. S., & Bertrand, D. (2014) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntt208 · Cited by 14
Cardiovascular Prevention (IV) The Importance of Treating Tobacco Dependence
McRobbie, H. J., & Thornley, S. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(08)60186-3 · Cited by 14
Goutier, W., Kloeze, M. B., & McCreary, A. C. (2013) · Addiction Biology · doi:10.1111/adb.12108 · Cited by 15
Ondachi, P. W., Castro, A. H., Bartkowiak, J., Luetje, C. W., Damaj, M. I., Mascarella, S. W., Navarro, H. A., & Carroll, F. I. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401602p · Cited by 14
Koga, M., Kanaoka, Y., Okamoto, M., Nakao, Y., Inada, K., Takayama, S., Kataoka, Y., & Yamauchi, A. (2019) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2019.11.002 · Cited by 14
Brain Nicotinic Receptors as Emerging Targets for Drug Addiction
Rahman, S. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385506-0.00008-9 · Cited by 14
Seyedaghamiri, F., Hosseini, L., Kazmi, S., Mahmoudi, J., Shanehbandi, D., Kalan, A. E., Rahbarghazi, R., Sadigh‐Eteghad, S., & Farhoudi, M. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.01.010 · Cited by 13
Esaki, H., Deyama, S., Izumi, S., Katsura, A., Nishikawa, K., Nishitani, N., & Kaneda, K. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109672 · Cited by 13
Liu, Y., Richardson, J. R., Tran, T. P., Al‐Muhtasib, N., Xie, T., Yenugonda, V. M., Sexton, H. G., Rezvani, A. H., Levin, E. D., Sahibzada, N., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4000374 · Cited by 13
Ohmura, Y., Sasamori, H., Tsutsui‐Kimura, I., Izumi, T., Yoshida, T., & Yoshioka, M. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.01.002 · Cited by 13
DiPalma, D. T., Rezvani, A. H., Willette, B. K. A., Wells, C., Slade, S. K., Hall, B. J., & Levin, E. D. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.11.002 · Cited by 13
Bashrahil, B., Taher, N. O., Alzahrani, Z., Alnabihi, A. N., Aldahlawi, A. K., AlKhathlan, M. K., & Alghamdi, S. (2023) · BMC Ophthalmology · doi:10.1186/s12886-023-03069-y · Cited by 13
Predicted Impact of Nicotine Reduction on Smokers with Affective Disorders
Gaalema, D. E., Miller, M. E., & Tidey, J. W. (2015) · Tobacco Regulatory Science · doi:10.18001/trs.1.2.5 · Cited by 13
Henderson, B. J., González-Cestari, T. F., Yi, B., Pavlovicz, R. E., Boyd, R. T., Li, C., Bergmeier, S. C., & McKay, D. B. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300035f · Cited by 12
Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers
Yardley, M. M., Mirbaba, M., & Ray, L. A. (2015) · CNS Drugs · doi:10.1007/s40263-015-0284-5 · Cited by 15
Touchette, J. C., Maertens, J. J., Mason, M. M., O’Rourke, K. Y., & Lee, A. M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.019 · Cited by 13
Graham, D. J., By, K., McKean, S. J., Mosholder, A. D., Kornegay, C. J., Racoosin, J. A., Young, J. C., Levenson, M. S., MaCurdy, T. E., Worrall, C. M., et al. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3678 · Cited by 13
Zaccarelli‐Magalhães, J., Sandini, T. M., Abreu, G., Petrocelli, B. M., Moreira, N. C. D. S., Reis-Silva, T. M., Lebrun, I., Flório, J. C., Ricci, E. L., Fukushima, A. R., et al. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.03.009 · Cited by 12
Madsen, H. B., Koghar, H. S., Pooters, T., Massalas, J. S., Drago, J., & Lawrence, A. J. (2014) · Addiction Biology · doi:10.1111/adb.12148 · Cited by 15
A behavioral economic perspective on smoking persistence in serious mental illness
Tidey, J. W. (2016) · Preventive Medicine · doi:10.1016/j.ypmed.2016.05.015 · Cited by 12
Spiros, Ä., Roberts, P., & Geerts, H. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.12.006 · Cited by 12
Discriminative Stimulus Properties of S(−)-Nicotine: “A Drug for All Seasons”
Rosecrans, J. A., & Young, R. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_3 · Cited by 12
Nicotinic Acetylcholine Receptors in HIV: Possible Roles During HAND and Inflammation
Capó-Vélez, C. M., Delgado‐Vélez, M., Báez-Pagán, C. A., & Lasalde‐Dominicci, J. A. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0603-8 · Cited by 12
Preclinical and clinical research on the discriminative stimulus effects of nicotine
Shoaib, M. C., & Perkins, K. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108063 · Cited by 12
Nicotinic Receptors: Role in Addiction and Other Disorders of the Brain
Sharma, G., & Vijayaraghavan, S. (2008) · Substance Abuse Research and Treatment · doi:10.1177/117822180800100005 · Cited by 16
Albayati, Z. A. F., Dwoskin, L. P., & Crooks, P. A. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020354 · Cited by 12
Varenicline: For smoking cessation
Rao, J., & Shankar, P. (1970) · Kathmandu University Medical Journal · doi:10.3126/kumj.v7i2.2714 · Cited by 12
Wu, J., Cippitelli, A., Zhang, Y., Debevec, G., Schoch, J., Ozawa, A., Yu, Y., Liu, H., Chen, W., Houghten, R. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01250 · Cited by 13
Anand, R., Stephanie, A., Ponath, G. D., Jordan, I., Nasir, M. I., & Susan, B. (2011) · InTech eBooks · doi:10.5772/20752 · Cited by 11
Hallucinations in the Context of Varenicline Withdrawal
LAINE, P., MARTTILA, J., & Lindeman, S. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08091370 · Cited by 12
Gao, R., Schneider, A. M., Mulloy, S., & Lee, A. M. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.16109 · Cited by 12
Jackson, A. E., Silk, S., Buhidma, Y., & Shoaib, M. C. (2016) · Addiction Biology · doi:10.1111/adb.12423 · Cited by 12
Dwoskin, L. P., Pivavarchyk, M., Joyce, B. M., Neugebauer, N. M., Zheng, G., Zhang, Z., Bardo, M. T., & Crooks, P. A. (2008) · Nebraska Symposium on Motivation/The Nebraska symposium on motivation · doi:10.1007/978-0-387-78748-0_4 · Cited by 12
Breining, S. R., Bencherif, M., Grady, S. R., Whiteaker, P., Marks, M. J., Wageman, C. R., Lester, H. A., & Yohannes, D. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.085 · Cited by 11
Ueno, K., Kiguchi, N., Kobayashi, Y., Saika, F., Wakida, N., Yamamoto, C., Maeda, T., Ozaki, M., & Kishioka, S. (2013) · Journal of Pharmacological Sciences · doi:10.1254/jphs.13172fp · Cited by 11
McGregor, A. L., D’Souza, G. X., Kim, D., & Tingle, M. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.021 · Cited by 11
Subtle Differences among 5-HT3AC, 5-HT3AD, and 5-HT3AE Receptors Are Revealed by Partial Agonists
Price, K. L., Hirayama, Y., & Lummis, S. C. R. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00416 · Cited by 11
Koga, M., Kanaoka, Y., Tashiro, T., Hashidume, N., Kataoka, Y., & Yamauchi, A. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.06.007 · Cited by 11
Functional Assay of Mammalian and Insect Olfactory Receptors Using Xenopus Oocytes
Luetje, C. W., Nichols, A. S., Castro, A., & Sherman, B. L. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-377-0_14 · Cited by 11
Double target concept for smoking cessation
Wu, J. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.137 · Cited by 11
Role of neuronal nicotinic acetylcholine receptors in cannabinoid dependence
Buzzi, B., Köşeli, E., Moncayo, L. V., Shoaib, M., & Damaj, M. I. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106746 · Cited by 10
Recent advances in gene manipulation and nicotinic acetylcholine receptor biology
Tammimäki, A., Horton, W. J., & Stitzel, J. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.014 · Cited by 10
Pharmacotherapy for tobacco cessation: Nicotine agonists, antagonists, and partial agonists
Karam‐Hage, M., & Cinciripini, P. M. (2007) · Current Oncology Reports · doi:10.1007/s11912-007-0072-6 · Cited by 10
Manetti, D., Garifulina, A. I., Bartolucci, G., Bazzicalupi, C., Bellucci, C., Chiaramonte, N., Dei, S., Mannelli, L. D. C., Ghelardini, C., Gratteri, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01372 · Cited by 10
More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder
Moerke, M. J., McMahon, L. R., & Wilkerson, J. L. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018028 · Cited by 11
Pittenger, S. T., Barrett, S. T., Chou, S., & Bevins, R. A. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.12.005 · Cited by 10
Metamodulation of presynaptic NMDA receptors: New perspectives for pharmacological interventions
Olivero, G., Grilli, M., Marchi, M., & Pittaluga, A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109570 · Cited by 10
Neurotensin and Alcohol Use Disorders: Towards a Pharmacological Treatment
Rodriguez, F. D., Sánchez, M. L., & Coveñas, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108656 · Cited by 10
The influence of acute varenicline administration on smoking and eating behavior in humans
Stoops, W. W., Vansickel, A. R., Glaser, P. E. A., & Rush, C. R. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.07.001 · Cited by 10
Varenicline improves motor and cognitive symptoms in early Huntington’s disease
McGregor, A. L., Dysart, J., Tingle, M. D., Russell, B., Kydd, R. R., & Finucane, G. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s111083 · Cited by 10
Zhou, X., Huang, Z., Song, Q., Xia, X., Cheng, A., Liu, Z., Wang, M., Ji, T., Aihemaiti, A., Xie, Y., et al. (2025) · Addiction · doi:10.1111/add.70235 · Cited by 10
The smoking cessation drug varenicline improves deficient P20–N40 inhibition in DBA/2 mice
Wildeboer, K. M., & Stevens, K. E. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.07.001 · Cited by 9
Cys-loop receptors on cannabinoids: All high?
Schmiedhofer, P. B., Vogel, F. D., Koniuszewski, F., & Ernst, M. C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1044575 · Cited by 9
Hauswirth, S. G., Kabat, A. G., Hemphill, M., Somaiya, K., Hendrix, L. H., & Gibson, A. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2022-0215 · Cited by 9
Ginsburg, B. C., & Lamb, R. J. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12285 · Cited by 9
Grebenstein, P. E., Harp, J. L., & Rowland, N. E. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.07.012 · Cited by 9
Ketcherside, A., Jagannathan, K., Dolui, S., Hager, N., Spilka, N. H., Nutor, C., Rao, H., Franklin, T. R., & Wetherill, R. R. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.2.289 · Cited by 10
Enantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective ?4?2-nAChR Ligands
Onajole, O. K., Eaton, J. B., Lukas, R. J., Brunner, D., Thiede, L., Caldarone, B. J., & Kozikowski, A. P. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500129k · Cited by 8
The role of nicotinic receptors in alcohol consumption
Kamens, H. M., Flarend, G., & Horton, W. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106705 · Cited by 8
Barış, E., Arıcı, A., & Tosun, M. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1392689 · Cited by 8
Grover disease may result from the impairment of keratinocytic cholinergic receptors
Paslin, D. A. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.08.015 · Cited by 8
Ortiz, C., Roncero, C., Miquel, L., & Casas, M. (2011) · Adicciones · doi:10.20882/adicciones.168 · Cited by 8
Koga, M., Kanaoka, Y., Sugiyama, K., Ohishi, K., Ejima, Y., Hisanaga, M., Kataoka, Y., & Yamauchi, A. (2017) · Toxicology · doi:10.1016/j.tox.2017.08.006 · Cited by 8
Nicotine Enhances the Hypnotic and Hypothermic Effects of Alcohol in the Mouse
Slater, C. A., Jackson, A. B., Muldoon, P. P., Dawson, A., O'Brien, M., Soll, L. G., Abdullah, R. A., Carroll, F. I., Tapper, A. R., Miles, M. F., et al. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12918 · Cited by 8
Reyes-Parada, M. I., & Iturriaga‐Vásquez, P. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1227317 · Cited by 8
Newcombe, D. A. L. (2015) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.1000222 · Cited by 7
Lu, Y., Sun, X., Fan, S., Wang, L., Song, M. O., & Hang, T. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.03.055 · Cited by 8
TC299423, a Novel Agonist for Nicotinic Acetylcholine Receptors
Wall, T. R., Henderson, B. J., Voren, G., Wageman, C. R., Deshpande, P., Cohen, B. N., Grady, S. R., Marks, M. J., Yohannes, D., Kenny, P. J., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00641 · Cited by 8
Naval Submarine Medical Research Laboratory
Roman, L. (2011) · Digital Commons @ Connecticut College (Connecticut College) · Cited by 8
Varenicline Prevents SARS-CoV-2 Infection In Vitro and in Rhesus MacaquesPreprint
Nau, J. A., Luthra, P., Lanzer, K. G., Szaba, F. M., Cookenham, T. S., & Carlson, E. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.29.450426 · Cited by 8
Ballesteros‐Sánchez, A., Borroni, D., De‐Hita‐Cantalejo, C., Sánchez‐González, M. C., Sánchez‐Gómez, S., Rocha‐de‐Lossada, C., & Sánchez‐González, J. (2023) · Contact Lens and Anterior Eye · doi:10.1016/j.clae.2023.102097 · Cited by 7
A Clinical Imperative: Assisting Patients Who Smoke to Reduce Their Risk of Cardiovascular Disease
Bullen, C., Whittaker, R., McRobbie, H. J., & Fagerström, K. O. (2007) · Preventive Cardiology · doi:10.1111/j.1520-037x.2007.06525.x · Cited by 7
Arunrungvichian, K., Chongruchiroj, S., Sarasamkan, J., Schüürmann, G., Brust, P., & Vajragupta, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176189 · Cited by 7
Tangmanussukum, P., Kawichai, T., Suratanee, A., & Plaimas, K. (2022) · PeerJ Computer Science · doi:10.7717/peerj-cs.1124 · Cited by 7
Varenicline in Autistic Disorder: Hypothesis and Case Report of Single-Patient Crossover
Arnold, L. E., Anand, R., & Aman, M. G. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0025 · Cited by 7
Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia
Montoya, I. D., & Vocci, F. J. (2007) · Journal of Dual Diagnosis · doi:10.1300/j374v03n03_09 · Cited by 7
The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions
Decker, M. W., Gopalakrishnan, M., & Meyer, M. D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.9.1027 · Cited by 7
A manic episode in a 64-year-old man: an adverse effect of varenicline
Ahmed, A. I. A. (2011) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2010.11.005 · Cited by 7
Nicotine- and cocaine-triggered methamphetamine reinstatement in female and male Sprague-Dawley rats
Pittenger, S. T., Chou, S., Barrett, S. T., Catalano, I., Lydiatt, M. F., & Bevins, R. A. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.07.003 · Cited by 7
Metadata
- Authors
- Mihalak, K. B., Carroll, F. I., & Luetje, C. W.
- Affiliations
- University of Miami (US)
- RTI International (US)
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2006-09
- Volume
- 70
- Issue
- 3
- Pages
- 801-805
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W2141246891
- Cited by
- 558
- References
- 26
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 7 · 2023: 23 · 2022: 14 · 2021: 15 · 2020: 20 · 2019: 19 · 2018: 22 · 2017: 32 · 2016: 41 · 2015: 40 · 2014: 44 · 2013: 48 · 2012: 36
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Miami
- U.S. Food and Drug Administration
- National Heart, Lung, and Blood Institute (T32HL007188)
- National Institute of Mental Health (MH-66038, R01MH066038)
- National Institute on Drug Abuse (R01DA012001, DA12001, DA08102, R01DA008102)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- varenicline, neuronal nicotinic acetylcholine receptors, alpha4beta2 receptor, partial agonists, full agonists, receptor selectivity, smoking cessation, cytisine derivatives
- MeSH terms
- Varenicline, Animals, Benzazepines, Neurons, Oocytes, Quinoxalines, Receptors, Nicotinic, Xenopus laevis, Nicotinic Agonists, Rats, alpha7 Nicotinic Acetylcholine Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
